|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Feys L, Descamps B, Vanhove C, Vral A,
Veldeman L, Vermeulen S, De Wagter C, Bracke M and De Wever O:
Radiation-induced lung damage promotes breast cancer
lung-metastasis through CXCR4 signaling. Oncotarget. 6:26615–26632.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cardoso F1, Harbeck N, Fallowfield L,
Kyriakides S and Senkus E; ESMO Guidelines Working Group. Locally
recurrent or metastatic breast cancer: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol.
23(Suppl 7): vii11–19. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Halyard MY, Pisansky TM, Dueck AC, Suman
V, Pierce L, Solin L, Marks L, Davidson N, Martino S, Kaufman P, et
al: Radiotherapy and adjuvant trastuzumab in operable breast
cancer: Tolerability and adverse event data from the NCCTG Phase
III Trial N9831. J Clin Oncol. 27:2638–2644. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schenone S, Brullo C, Musumeci F, Radi M
and Botta M: ATP-competitive inhibitors of mTOR: An update. Curr
Med Chem. 18:2995–3014. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mallya S, Fitch BA, Lee JS, So L, Janes MR
and Fruman DA: Resistance to mTOR kinase inhibitors in lymphoma
cells lacking 4EBP1. PLoS One. 9:e888652014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li S, Oh YT, Yue P, Khuri FR and Sun SY:
Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent
degradation of sterol regulatory element-binding protein 1 (SREBP1)
and suppresses lipogenesis in cancer cells. Oncogene. 35:642–50.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mazan-Mamczarz K, Peroutka RJ, Steinhardt
JJ, Gidoni M, Zhang Y, Lehrmann E, Landon AL, Dai B, Houng S,
Muniandy PA, et al: Distinct inhibitory effects on mTOR signaling
by ethanol and INK128 in diffuse large B-cell lymphoma. Cell Commun
Signal. 13:152015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang H, Dou J, Yu Y, Zhao Y, Fan Y, Cheng
J, Xu X, Liu W, Guan S, Chen Z, et al: mTOR ATP-competitive
inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC
signaling. Apoptosis. 20:50–62. 2015. View Article : Google Scholar :
|
|
11
|
Gild ML, Landa I, Ryder M, Ghossein RA,
Knauf JA and Fagin JA: Targeting mTOR in RET mutant medullary and
differentiated thyroid cancer cells. Endocr Relat Cancer.
20:659–667. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hsieh AC, Liu Y, Edlind MP, Ingolia NT,
Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, et
al: The translational landscape of mTOR signalling steers cancer
initiation and metastasis. Nature. 485:55–61. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Janes MR, Vu C, Mallya S, Shieh MP, Limon
JJ, Li LS, Jessen KA, Martin MB, Ren P, Lilly MB, et al: Efficacy
of the investigational mTOR kinase inhibitor MLN0128/INK128 in
models of B-cell acute lymphoblastic leukemia. Leukemia.
27:586–594. 2013. View Article : Google Scholar
|
|
14
|
Wilson-Edell KA, Yevtushenko MA,
Rothschild DE, Rogers AN and Benz CC: mTORC1/C2 and pan-HDAC
inhibitors synergistically impair breast cancer growth by
convergent AKT and polysome inhibiting mechanisms. Breast Cancer
Res Treat. 144:287–298. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pan H, Xu LH, Ouyang DY, Wang Y, Zha QB,
Hou XF and He XH: The second-generation mTOR kinase inhibitor
INK128 exhibits anti-inflammatory activity in
lipopolysaccharide-activated RAW 264.7 cells. Inflammation.
37:756–765. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
García-García C, Ibrahim YH, Serra V,
Calvo MT, Guzmán M, Grueso J, Aura C, Pérez J, Jessen K, Liu Y, et
al: Dual mTORC1/2 and HER2 blockade results in antitumor activity
in preclinical models of breast cancer resistant to anti-HER2
therapy. Clin Cancer Res. 18:2603–2612. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gökmen-Polar Y, Liu Y, Toroni RA, Sanders
KL, Mehta R, Badve S, Rommel C and Sledge GW Jr: Investigational
drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral
antitumor activity in human breast cancer xenograft models. Breast
Cancer Res Treat. 136:673–682. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hayman TJ, Wahba A, Rath BH, Bae H, Kramp
T, Shankavaram UT, Camphausen K and Tofilon PJ: The ATP-competitive
mTOR inhibitor INK128 enhances in vitro and in vivo
radiosensitivity of pancreatic carcinoma cells. Clin Cancer Res.
20:110–119. 2014. View Article : Google Scholar :
|
|
19
|
Woo YM, Shin Y, Lee EJ, Lee S, Jeong SH,
Kong HK, Park EY, Kim HK, Han J, Chang M, et al: Inhibition of
aerobic glycolysis represses Akt/mTOR/HIF-1α axis and restores
tamoxifen sensitivity in antiestrogen-resistant breast cancer
cells. PLoS One. 10:e01322852015. View Article : Google Scholar
|
|
20
|
Deng L, Chen J, Zhong XR, Luo T, Wang YP,
Huang HF, Yin LJ, Qiu Y, Bu H, Lv Q, et al: Correlation between
activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer
in Chinese women. PLoS One. 10:e01205112015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu ZG, Liu L, Xu LH, Yi W, Tao YL, Tu ZW,
Li MZ, Zeng MS and Xia YF: Bmi-1 induces radioresistance in MCF-7
mammary carcinoma cells. Oncol Rep. 27:1116–1122. 2012.PubMed/NCBI
|
|
22
|
Chen YH, Wei MF, Wang CW, Lee HW, Pan SL,
Gao M, Kuo SH, Cheng AL and Teng CM: Dual phosphoinositide
3-kinase/mammalian target of rapamycin inhibitor is an effective
radiosensitizer for colorectal cancer. Cancer Lett. 357:582–590.
2015. View Article : Google Scholar
|
|
23
|
Li K, Cao RJ, Zhu XJ, Liu XY, Li LY and
Cui SS: Erythropoietin attenuates the apoptosis of adult neurons
after brachial plexus root avulsion by downregulating JNK
phosphorylation and c-Jun expression and inhibiting c-PARP
cleavage. J Mol Neurosci. 56:917–925. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu R, Li W, Xu Y, Wan J and Zhang Z:
Upregulation of BTG1 enhances the radiation sensitivity of human
breast cancer in vitro and in vivo. Oncol Rep. 34:3017–3024.
2015.PubMed/NCBI
|
|
25
|
Warren LE, Punglia RS, Wong JS and Bellon
JR: Management of the regional lymph nodes following
breast-conservation therapy for early-stage breast cancer: An
evolving paradigm. Int J Radiat Oncol Biol Phys. 90:772–777. 2014.
View Article : Google Scholar
|
|
26
|
Zhu J, Ye Q, Chang L, Xiong W, He Q and Li
W: Upregulation of miR-195 enhances the radiosensitivity of breast
cancer cells through the inhibition of BCL-2. Int J Clin Exp Med.
8:9142–9148. 2015.PubMed/NCBI
|
|
27
|
Lou HZ, Weng XC, Pan HM, Pan Q, Sun P, Liu
LL and Chen B: The novel mTORC1/2 dual inhibitor INK-128 suppresses
survival and proliferation of primary and transformed human
pancreatic cancer cells. Biochem Biophys Res Commun. 450:973–978.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Radhakrishnan SK, Feliciano CS, Najmabadi
F, Haegebarth A, Kandel ES, Tyner AL and Gartel AL: Constitutive
expression of E2F-1 leads to p21-dependent cell cycle arrest in S
phase of the cell cycle. Oncogene. 23:4173–4176. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Raj K, Ogston P and Beard P:
Virus-mediated killing of cells that lack p53 activity. Nature.
412:914–917. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Abdel-Fatah TM, Arora A, Moseley PM, Perry
C, Rakha EA, Green AR, Chan SY, Ellis IO and Madhusudan S: DNA
repair prognostic index modelling reveals an essential role for
base excision repair in influencing clinical outcomes in ER
negative and triple negative breast cancers. Oncotarget.
6:21964–21978. 2015. View Article : Google Scholar : PubMed/NCBI
|
